Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics Inc (NASDAQ: SRPT) is a leader in precision genetic medicine, pioneering RNA-targeted therapies for rare neuromuscular and infectious diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on SRPT's scientific advancements, regulatory milestones, and strategic initiatives.
Access real-time press releases covering clinical trial developments, partnership announcements, and financial disclosures. Our curated news collection simplifies tracking SRPT's progress in bringing transformative treatments to underserved patient populations through its proprietary platform technologies.
Key updates include FDA communications regarding novel therapies, research collaborations advancing genetic medicine, and operational developments impacting SRPT's therapeutic pipeline. All content is verified through primary sources to ensure accuracy and timeliness.
Bookmark this page for streamlined access to Sarepta's latest achievements in exon-skipping therapies and gene editing innovations. Stay informed about critical developments shaping this biopharmaceutical innovator's trajectory in targeted genetic treatments.
Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 28 newly hired employees on November 30, 2020, as part of its 2014 Employment Commencement Incentive Plan. These awards include options to purchase 35,770 shares and 15,000 restricted stock units (RSUs). The options have an exercise price of $140.86 per share, equivalent to the stock's closing price on the grant date. Both options and RSUs will vest over four years, contingent on continued employment with the company.
Sarepta Therapeutics (NASDAQ:SRPT) announced its participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 3:30 p.m. E.T. The event will be available via a live webcast on Sarepta's website and archived for 90 days. Sarepta is recognized for its innovations in precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy (DMD), with over 40 programs underway across various therapeutic modalities including RNA and gene therapy.
Sarepta Therapeutics (NASDAQ:SRPT) has been recognized by The Boston Globe as one of the Top Places to Work in 2020 in the large company category. This ranking is based on employee surveys addressing company direction, management, and work benefits. CEO Doug Ingram highlighted the dedication of employees in maintaining a positive culture during a challenging year. The company continues to innovate in precision genetic medicine and has implemented several initiatives to support employees through the pandemic, including caregiving benefits and virtual wellness seminars.
Sarepta Therapeutics (NASDAQ:SRPT) reported a 23% increase in third-quarter 2020 net product sales, totaling $121.4 million, compared to $99.0 million in Q3 2019. Despite challenges from the pandemic, the company advanced its pipeline, with FDA acceptance of the NDA for casimersen and positive data from gene therapy trials, including SRP-9001 and SRP-9003. However, Sarepta reported a net loss of $196.5 million for the quarter. The company's cash reserves increased to $1.8 billion due to strategic financing activities.
Sarepta Therapeutics (NASDAQ:SRPT) announced plans to commence dosing with commercial-process material for SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy, before the end of 2020. Following discussions with the U.S. FDA's OTAT, Sarepta aims to expedite a new clinical study (Study 103) focused on safety and expression in up to 10 patients. The company also anticipates a data read-out from an ongoing trial (Study 102) in early 2021. This progress is crucial for advancing treatment options for patients suffering from this rare disease.
Sarepta Therapeutics (NASDAQ:SRPT) is set to participate in the 29th Annual Credit Suisse Virtual Healthcare Conference on November 9, 2020, at 3:30 p.m. E.T. Senior management will engage in a fireside chat, which will be available via live webcast on the company's investor relations page. The presentation will be archived for 90 days post-event. Sarepta focuses on precision genetic medicine, particularly in Duchenne muscular dystrophy and gene therapies for various rare diseases, boasting over 40 programs under development.
Sarepta Therapeutics (NASDAQ:SRPT) announced the grant of equity awards on October 30, 2020, to 12 new employees as part of its 2014 Employment Commencement Incentive Plan. In total, the employees received options to purchase 20,835 shares and 8,385 restricted stock units (RSUs). The options have an exercise price of $135.91 per share, equal to the closing price on the grant date. Options vest over four years, while RSUs vest annually, contingent upon continued employment.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce its third quarter 2020 financial results on November 5, 2020, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss results and provide a corporate update. The call can be accessed by dialing specific numbers for domestic and international callers, and will also be available via webcast. Sarepta continues to make advancements in precision genetic medicine, focusing on therapies for rare diseases such as Duchenne muscular dystrophy and various gene therapies.
AavantiBio, a new gene therapy company, has secured $107 million in Series A financing led by notable life sciences investors, including Sarepta Therapeutics (NASDAQ: SRPT), which contributed $15 million. The company, co-founded by experts Barry Byrne and Manuela Corti, will focus on developing therapies for Friedreich's Ataxia, a rare genetic disorder affecting the nervous system and heart. Bo Cumbo, formerly Sarepta's CCO, has been appointed CEO. AavantiBio aims to leverage its connections with the University of Florida’s Powell Gene Therapy Center to enhance its research capabilities.
Sarepta Therapeutics (NASDAQ: SRPT) announced the 21 recipients of Route 79, The Duchenne Scholarship Program, aiding students with Duchenne muscular dystrophy in pursuing higher education. Each recipient receives up to $5,000, showcasing their community involvement and personal achievements. This is the third year of the program, reflecting Sarepta's commitment to supporting the Duchenne community, especially amid challenges posed by COVID-19. The selection process is overseen by an independent committee to ensure fairness and anonymity in evaluating applicants.
